NCT00189696View on ClinicalTrials.gov

Phase 3 Study of YM060 in Patients With Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
Irritable Bowel Syndrome
Interventions
DRUG

YM060

Trial Locations (4)

Unknown

Chubu Region

Kanto Region

Shikoku Region

Tohoku Region

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY

NCT00189696 - Phase 3 Study of YM060 in Patients With Diarrhea-predominant Irritable Bowel Syndrome (d-IBS) | Biotech Hunter | Biotech Hunter